Advanced search
Publication Cover
Journal of Blood Medicine Volume 15, 2024 - Issue
Submit an article Journal homepage
98
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Successful Treatment of Steroid-Refractory Immune Thrombocytopenia in a Patient Developing Multiple Myeloma While on Immune Checkpoint Inhibitor Therapy for Lung Cancer: A Case Report

Yudai HayashiDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu City, Tokyo, Japan
,
Masao TsukadaDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu City, Tokyo, JapanCorrespondence[email protected]
,
Daisuke ShinodaDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu City, Tokyo, Japan
,
Marina MatsuiDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu City, Tokyo, Japan
,
Kanichi IwamaDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu City, Tokyo, Japan
,
Koichi KajiwaraDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu City, Tokyo, Japan
&
Kozai YasujiDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Fuchu City, Tokyo, Japan
 show all
Pages 285-290 | Received 15 Mar 2024, Accepted 12 Jun 2024, Published online: 20 Jun 2024

References

  • Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi:10.1038/s41572-020-0160-6
  • Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z
  • Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer. 2018;6(1):49. doi:10.1186/s40425-018-0365-3
  • Rajapakse P, Andanamala H. Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy. World J Oncol. 2022;13(2):49–52. doi:10.14740/wjon1464
  • Haddad TC, Zhao S, Li M, et al. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol Immunother. 2022;71(5):1157–1165. doi:10.1007/s00262-021-03068-2
  • Hasegawa T, Ozaki Y, Inoue T, et al. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature. J Med Case Rep. 2019;13(1):316. doi:10.1186/s13256-019-2245-y
  • Ohashi T, Takase-Minegishi K, Maeda A, et al. Incidence and risk of hematological adverse events associated with immune checkpoint inhibitors: a systematic literature review and meta-analysis. J Hematol. 2023;12(2):66–74. doi:10.14740/jh1090
  • Calvo R. Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia. Front Pharmacol. 2019;10:454. doi:10.3389/fphar.2019.00454
  • Dong HH, Li J, Kang L, Wei Q, Li Y. Simultaneous multiple myeloma and non-small cell lung carcinoma: a case report and review of the literature. Oncol Lett. 2022;23(6):195. doi:10.3892/ol.2022.13315
  • Pföhler C, Eichler H, Burgard B, Krecké N, Müller CSL, Vogt T. A case of immune thrombocytopenia as a rare side effect of an Immunotherapy with PD1-blocking agents for metastatic melanoma. Transfus Med Hemother. 2017;44(6):426–428. doi:10.1159/000479237
  • Leroy L, Lafarge X, Blouin L, et al. A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor. Ann Oncol. 2018;29(2):514–515. doi:10.1093/annonc/mdx693
  • Faller E, Chapman L, Enright H, et al. Immune thrombocytopenia purpura associated with multiple myeloma. Ann Hematol. 2016;95(8):1371–1372. doi:10.1007/s00277-016-2694-y
  • Sarfraz H, Anand K, Liu S, et al. Multiple myeloma with concurrent immune thrombocytopenic purpura. Ecancermedicalscience. 2020;14:1012. doi:10.3332/ecancer.2020.1012
  • Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75–81. doi:10.1016/s2352-3026(15)00003-4
  • Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124–1135. doi:10.3324/haematol.2019.218883
  • Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):51. doi:10.1186/s13045-016-0283-0
  • Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706–3714. doi:10.1002/cncr.31629
  • Ito M, Kanda S, Yoshida T, et al. Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient. Lung Cancer. 2020;146:362–365. doi:10.1016/j.lungcan.2020.05.015
  • Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/jco.2017.77.6385
  • Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. doi:10.1200/jco.21.01440

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.